All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @thisisjustme77 on TikTok · 190s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @thisisjustme77's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:01Good morning everybody, it is the second of June.
  2. 0:07And I have had a breakthrough.
  3. 0:11Okay, so I haven't posted for a few days.
  4. 0:15I've now feel I'm a fully fledged Mongeau user.
  5. 0:19So if you've seen my previous videos,
  6. 0:23obviously I've been struggling to actually feel anything.
  7. 0:28I just felt completely the same.
  8. 0:30I didn't wish for side effects, obviously.
  9. 0:33Although I have had a little bit of trouble going to the toilet,
  10. 0:38but I know I just needed the fiber.
  11. 0:40So all brownie walls.
  12. 0:42And it sorted it out.
  13. 0:44Anyway, yes.
  14. 0:46So I do feel like I've had a breakthrough.
  15. 0:49I have got suppression.
  16. 0:52Yay!
  17. 0:53Not loads, not like a carne, if anything like that.
  18. 0:57So I've got a little bit of honey,
  19. 1:00if anything like that.
  20. 1:01So I know I've got tea, but struggling a little bit.
  21. 1:05So I had a, what did I have yesterday?
  22. 1:08So yesterday was probably the first day that I was like,
  23. 1:11yes, I feel like this is now working.
  24. 1:14So yesterday I had one of those multi-mills,
  25. 1:19I have my smoothie.
  26. 1:22So what I do, I have a smoothie with spinach
  27. 1:26and iron and strawberries and then
  28. 1:29act to melon some oat milk.
  29. 1:32So I had that hands, like loads of water,
  30. 1:35as always, with water.
  31. 1:38Some scrummed egg.
  32. 1:41Yeah, but I feel better now.
  33. 1:45And then the second week, so like I said before,
  34. 1:49if you haven't seen my previous videos,
  35. 1:51please check them out.
  36. 1:53So I'm now on, okay, seven, eight, nine, ten.
  37. 1:57I'm now on day ten of Manjaro.
  38. 2:01I have had a message this morning to say,
  39. 2:03order some more.
  40. 2:04I'm in an hour and whether to go up now.
  41. 2:07So I was going to go up to the five milligram.
  42. 2:09If anybody could give me some tips on that,
  43. 2:11really appreciate it, because I'm on the 2.5, obviously now,
  44. 2:14but it's only my second week.
  45. 2:16I think it's just taking time to get into my system
  46. 2:18and to get my body used to it.
  47. 2:21And it's all good.
  48. 2:22So I don't feel like it's not working anymore.
  49. 2:26I don't feel like I've been sold a moody one, basically.
  50. 2:31So yeah, that's me for today.
  51. 2:33And I shall check in again and let you all know how I'm getting on.
  52. 2:38I haven't weighed myself for a few days.
  53. 2:40I think I'm just stable for now.
  54. 2:43I don't want to be obsessed with weighing myself.
  55. 2:46It's about for me.
  56. 2:48It's about losing interest and feeling comfortable in my clothes,
  57. 2:51especially jeans.
  58. 2:52I mean, jeans are the things that you don't get that hanging over
  59. 2:55from muffin top and just being able to sit down actually comfortable
  60. 2:59in a pair of jeans.
  61. 3:01That's what I want to do.
  62. 3:04Okay, so thanks for following.
  63. 3:06And yeah, like my videos.
  64. 3:08Thank you.
  65. 3:09Bye.

@thisisjustme77's GLP-1 claims need fact-checking

Sammy_mj

TikTok creator

14.2K viewsWatch on TikTok

Quick answer

This creator is on day ten of tirzepatide 2.5 mg, the standard four-week titration dose before escalation to 5 mg. Delayed appetite suppression onset at this dose is pharmacologically expected, as meaningful GIP and GLP-1 receptor engagement increases at higher doses. Constipation managed with dietary fiber is an appropriate first-line response to the GI motility effects of this drug class.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @thisisjustme77's GLP-1 claims need fact-checking, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@thisisjustme77's GLP-1 claims need fact-checking should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@thisisjustme77's GLP-1 claims need fact-checking" from Sammy_mj. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This creator is on day ten of tirzepatide 2.

The reason this review is not generic is the source wording and the canonical claim label "glp1 tiktok 7511281357557959958." In this clip, the useful excerpt is: "Good morning everybody, it is the second of June." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide-related constipation affects approximately 11 percent of users in clinical trials (SURMOUNT-1, Jastreboff et al.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

This creator is on day ten of tirzepatide 2.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This creator is on day ten of tirzepatide 2.5 mg, the standard four-week titration dose before escalation to 5 mg. Delayed appetite suppression onset at this dose is pharmacologically expected, as meaningful GIP and GLP-1 receptor engagement increases at higher doses. Constipation managed with dietary fiber is an appropriate first-line response to the GI motility effects of this drug class.
  • The 2.5 mg tirzepatide starting dose is a titration dose for tolerability, not a therapeutic dose. Feeling little effect in the first week is expected and documented across the SURPASS trial program.
  • Tirzepatide-related constipation affects approximately 11 percent of users in clinical trials (SURMOUNT-1, Jastreboff et al., 2022). Increasing dietary fiber is appropriate first-line management.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The 2.5 mg tirzepatide starting dose is a titration dose for tolerability, not a therapeutic dose. Feeling little effect in the first week is expected and documented across the SURPASS trial program.
  • Tirzepatide-related constipation affects approximately 11 percent of users in clinical trials (SURMOUNT-1, Jastreboff et al., 2022). Increasing dietary fiber is appropriate first-line management.
  • Standard dose escalation for tirzepatide is every four weeks minimum, per the approved label. Moving up after ten days because effects just started is premature and increases GI side effect risk.
  • Dose-dependent appetite suppression in tirzepatide is tied to greater receptor occupancy at 5 mg, 10 mg, and 15 mg. Week one at 2.5 mg is not predictive of long-term response.
  • Protein intake matters more than most GLP-1 users realize. Suppressed appetite can lead to inadequate protein consumption, which risks lean muscle loss during weight reduction (Wilding et al., 2021, NEJM).
  • Non-scale goals like clothing fit and physical comfort are clinically valid targets and are associated with better long-term adherence than scale-only tracking (Tronieri et al., 2023, Obesity Reviews).
  • Dose escalation decisions should come from a prescriber reviewing tolerability and response, not from an app notification or peer advice in TikTok comments.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @thisisjustme77 actually say?

After ten days on tirzepatide at the 2.5 mg starting dose, this creator says they finally felt appetite suppression for the first time. They described feeling "like this is now working" after a day where they ate a smoothie, scrambled eggs, and not much else. They also mentioned constipation that resolved after adding fiber, and they're considering whether to move to the 5 mg dose. Their stated goal is fitting comfortably in jeans, not watching the scale obsessively. That is, genuinely, a more reasonable framing than most GLP-1 content you'll see on this platform.

Does the science back this up?

On the core timeline claim, yes, mostly. The 2.5 mg starting dose of tirzepatide is a titration dose, not a therapeutic dose. It exists to let your gut adjust, not to drive meaningful appetite suppression. Frías et al. (2021, New England Journal of Medicine), the SURPASS-2 trial, showed that meaningful weight loss and appetite effects scaled with dose, with 5 mg and above producing significantly greater outcomes than the initiation dose. Feeling little at 2.5 mg in week one is expected, not a product failure.

The fiber fix for constipation is also well-supported. GLP-1 and GIP receptor agonists slow gastric motility, and constipation is one of the most commonly reported gastrointestinal side effects, affecting roughly 11 percent of tirzepatide users in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Dietary fiber is a standard first-line response before considering laxatives or dose adjustments.

What did they get wrong (or right)?

There is nothing factually wrong in this video, which is somewhat unusual for GLP-1 content on TikTok. The creator did not overclaim. They did not say tirzepatide "melts fat" or "resets your metabolism." They described their subjective experience accurately and with appropriate uncertainty.

One thing worth flagging: the creator mentions getting a message asking whether to "go up now" to 5 mg after just ten days. Standard prescribing guidance, as outlined in the Mounjaro US label, is to stay at each dose for at least four weeks before titrating. Moving up after ten days because suppression just kicked in would be premature and could increase GI side effect risk. That decision should go through their prescriber, not a message prompt from an app.

The food choices described, a spinach and berry smoothie with oat milk, scrambled eggs, plenty of water, are genuinely solid. No complaints there.

What should you actually know?

The 2.5 mg starting dose of tirzepatide is designed for tolerability, not effect. If you felt nothing in week one, that is not a malfunction. The therapeutic action builds with dose and time. Wróbel et al. (2023, Diabetes, Obesity and Metabolism) noted that appetite-regulating effects of dual GIP/GLP-1 agonists like tirzepatide are dose-dependent and receptor-saturation-dependent, meaning the starting dose occupies relatively few receptors compared to higher maintenance doses.

On the dose escalation question: do not let an app or a notification decide when you go up. Four weeks at each dose is the standard titration interval. Going faster increases the likelihood of nausea, vomiting, and gastroparesis symptoms without meaningfully accelerating weight loss outcomes. Your prescriber should be making that call based on your tolerability, not a prompt.

And the jeans goal? Honestly, that is a reasonable functional health target. Research consistently shows that patient-centered, non-scale outcomes improve medication adherence and long-term success (Tronieri et al., 2023, Obesity Reviews). Fixating only on the number can lead to frustration during normal weight fluctuation plateaus.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Sammy_mj · TikTok creator

14.2K views on this video

@thisisjustme77's GLP-1 claims need fact-checking

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the 2.5 mg tirzepatide starting dose?

The 2.5 mg tirzepatide starting dose is a titration dose for tolerability, not a therapeutic dose. Feeling little effect in the first week is expected and documented across the SURPASS trial program.

What does the video say about tirzepatide-related constipation affects approximately 11 percent of users in clinical?

Tirzepatide-related constipation affects approximately 11 percent of users in clinical trials (SURMOUNT-1, Jastreboff et al., 2022). Increasing dietary fiber is appropriate first-line management.

What does the video say about standard dose escalation for tirzepatide?

Standard dose escalation for tirzepatide is every four weeks minimum, per the approved label. Moving up after ten days because effects just started is premature and increases GI side effect risk.

Dose-dependent appetite suppression in tirzepatide is tied to greater receptor occupancy at 5 mg, 10 mg, and 15 mg. Week one at 2.5 mg is not predictive of long-term response?

Dose-dependent appetite suppression in tirzepatide is tied to greater receptor occupancy at 5 mg, 10 mg, and 15 mg. Week one at 2.5 mg is not predictive of long-term response.

What does the video say about protein intake matters more than most glp-1 users realize. suppressed?

Protein intake matters more than most GLP-1 users realize. Suppressed appetite can lead to inadequate protein consumption, which risks lean muscle loss during weight reduction (Wilding et al., 2021, NEJM).

What does the video say about non-scale goals like clothing fit?

Non-scale goals like clothing fit and physical comfort are clinically valid targets and are associated with better long-term adherence than scale-only tracking (Tronieri et al., 2023, Obesity Reviews).

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Sammy_mj, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.